S&P Futures
5,896.00 -10.00 (-0.17%) Dow Futures
43,485.00 -33.00 (-0.08%) Nasdaq Futures
20,415.00 -68.50 (-0.33%) Russell 2000 Futures
2,292.40 +1.20 (+0.05%) Crude Oil
70.12 +0.90 (+1.30%) Gold
2,749.40 +19.40 (+0.71%)
Idorsia Ltd (IDIA.SW)
- GlobeNewswire
New data on aprocitentan to be presented at the ASN Kidney Week 2024
Allschwil, Switzerland – October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of Nephrology (ASN) Kidney Week 2024, taking place in San Diego, CA, October 23–27, 2024. The following oral and poster presentations will be held, highlighting the promising results of using aprocitentan for patients with hypertension not adequately controlled with other medications, with positive eff
- GlobeNewswire
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with chronic insomnia, will be presented at Sleep Europe 2024 – the 27th Congress of the European Sleep Research Society (ESRS), taking place in Seville, Spain, September 24–27, 2024. The following posters will be presented: Lederer K, et al. Efficacy and safety of daridorexant in patients with chroni
